Dose-Dependent Link Found Between Ultraprocessed Food and Chronic Disease Risk
A meta-analysis of 51 prospective cohort studies involving over 8.8 million participants found that each additional 100 grams of ultraprocessed food consumed daily was associated with higher risks of cardiovascular events, cancer, all-cause mortality, and metabolic syndrome or diabetes. The authors suggest that primary care clinicians could advise patients to gradually reduce ultraprocessed food intake to about 10–20% of daily energy, favoring minimally processed alternatives. The evidence is observational, so causality remains unproven.
The meta-analysis examined 51 prospective cohort studies encompassing more than 8.8 million people, with researchers tracking dose-response relationships between ultraprocessed food intake and health outcomes. A daily increase of 100 grams — equivalent to roughly two hot dogs, one large store-bought cookie, or four servings of potato chips — corresponded to elevated risk across cardiovascular events, cancer, all-cause mortality, and metabolic syndrome or diabetes. Ultraprocessed foods are estimated to supply over half of calories in the typical American diet.
The study authors proposed that primary care clinicians might guide patients toward reducing ultraprocessed food consumption to approximately 10–20 percent of daily energy intake, emphasizing replacement with minimally processed alternatives rather than simple restriction. Notably, the FDA recently completed work on the federal government's first formal definition of ultraprocessed food, which has been submitted to the White House for review. However, the evidence base remains observational, and confounding factors such as socioeconomic status may partly explain the associations.
This research could influence how primary care physicians frame dietary advice, potentially shifting conversations toward gradual reduction rather than absolute avoidance. Lower-income populations, who tend to consume more ultraprocessed foods and face greater chronic disease burdens, may be most affected by any resulting guidance — though affordability of minimally processed alternatives remains a barrier. The findings may also accelerate regulatory discussions around food labeling and definitions, while the observational nature of the evidence means clinicians and policymakers should weigh recommendations cautiously until stronger causal data emerge.